Pluristem Therapeutics CEO Zami Aberman's 2013 pay rises 11% to $1.7M

Pluristem Therapeutics reports 2013 executive compensation

By ExecPay News

Published: March 31, 2014

Pluristem Therapeutics reported fiscal year 2013 executive compensation information on March 31, 2014.
In 2013, two executives at Pluristem Therapeutics received on average a compensation package of $1.4M, a 13% increase compared to previous year.
Average pay of disclosed executives at Pluristem Therapeutics
Zami Aberman, Chief Executive Officer, received $1.7M in total, which increased by 11% compared to 2012. 65% of Aberman's compensation, or $1.1M, was in stock awards. Aberman also received $75K in bonus, $489K in salary, as well as $21K in other compensation.
Yaky Yanay, Chief Financial Officer, received a compensation package of $1.1M, which increased by 15% compared to previous year. 68% of the compensation package, or $770K, was in stock awards.
Pluristem Therapeutics' fiscal year ends on June 30.

Related executives

Zami Aberman

Pluristem Therapeutics

Chairman

Yaky Yanay

Pluristem Therapeutics

Chief Executive Officer

You may also like

Source: SEC filing on March 31, 2014.